Home Challenging Results TrialWatch: Lilly’s Lartruvo Fails Study

TrialWatch: Lilly’s Lartruvo Fails Study


As reported in CNBC, Eli Lilly said on Friday its cancer treatment Lartruvo, approved on an accelerated basis in 2016, failed to improve patient survival in a long-term study and will no longer be prescribed. The news drove its shares down 3% before the bell. The company said it expects to take a charge in the first quarter of 2019 as a result of the failure and will have an impact on its full-year 2019 forecast.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.